The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

The vaccine doesn't prevent cancer from happening in the first place, but an early-phase trial found it could reduce the odds ...

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

RAS is the most mutated oncogene in cancer (about 30% rate), where mutations in KRAS are the most prevalent. The approval of covalent KRAS G12C inhibitors has shown allosteric inhibition of KRAS to be ...

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...

Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...